United Therapeutics Corp. (UTHR) is in the Pharma Industry

• Sort by
• View by Content Type

• 5 Potential Buyout Targets in Biotech - Barron's

  Bristol-Myers Squibb BMY made a $4.5B bid for the shares of ImClone IMCL it doesn't already own. Roche Holdings (RHHBY.PK) made a $44B offer for the shares of Genetech DNA it doesn't own. Both targets want the bid prices raised. Barron's Lawrence Strauss says these are just the two latest...

  External links 2008-08-17

  Tags: Biotech, Alexion Pharmaceuticals Inc., Amylin Pharmaceuticals Inc., Bristol-Myers Squibb Co., Genentech Inc., ImClone Systems Inc., Eli Lilly & Co., Merck & Co. Inc., Onyx Pharmaceuticals Inc., Pfizer Inc., United Therapeutics Corp., Vertex Pharmaceuticals Inc., Wyeth

• A Biotech Bloom in July

  Option Dragon submits: The best performing sector in the past month has been biotech. With investors flocking to safety due to recent financial turmoil and the sharp correction in energy, funds and investors have been warming up to biotech. The biotech sector is not without its large risks though and...

  External links 2008-07-28

  Tags: Celgene Corp., Biotech, Amgen Inc., Alexion Pharmaceuticals Inc., Acorda Therapeutics Inc., Onyx Pharmaceuticals Inc., Gilead Sciences Inc., Genentech Inc., OSI Pharmaceuticals Inc., United Therapeutics Corp.

• United Therapeutics Corp. Q1 2008 Earnings Call Transcript

  United Therapeutics Corp. Q1 2008 Earnings Call Transcript

  Earnings calls 2008-05-02

  Tags: Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance, United Therapeutics Corp.

• United Therapeutics Corp. Q4 2007 Earnings Call Transcript

  United Therapeutics Corp. Q4 2007 Earnings Call Transcript

  Earnings calls 2008-02-19

  Tags: Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance, United Therapeutics Corp.

Additional Resources

• United Therapeutics Reports Second Quarter 2008 Financial Results

  - Revenues of $68.6 Million, Increase of 32% Over Second Quarter 2007 - EPS of $0.63 per Basic Share, Increase of 125% Over Second Quarter 2007 - Earnings Before Non-Cash Charges of $1.36 per Basic Share, Increase of 56% Over Second Quarter 2007 SILVER...

  Articles 2008-07-31

• United Therapeutics to Announce Second Quarter 2008 Financial Results Before Market Open on Thursday, July 31, 2008

  SILVER SPRING, Md., July 24 /PRNewswire-FirstCall/ -- United Therapeutics Corporation announced today that it will release its 2008 second quarter financial results before the open of market on Thursday, July 31, 2008. United Therapeutics will host a half-hour teleconference on Thursday, July 31, 2008, at 9:00...

  Articles 2008-07-24

• The Daily Record News Summaries: July 1, 2008

  Legg to protect 3 funds Legg Mason Inc. said it entered agreements to protect three money- market funds against potential losses that will cut earnings in the three months ended today by 64 cents a diluted share. The Baltimore- based money manager said...

  Articles 2008-07-01

• New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration

  SILVER SPRING, Md., June 30 /PRNewswire-FirstCall/ -- United Therapeutics Corporation and its wholly-owned subsidiary, Lung Rx, Inc., announced today the submission of a New Drug Application NDA to the U.S. Food and Drug Administration FDA for marketing approval of an inhaled formulation of treprostinil ITRE...

  Articles 2008-06-30

• Mergent, Inc. Announces Quarterly Rebalancing of HealthShares™ Indexes

  NEW YORK, June 17 /PRNewswire/ -- Mergent, Inc., administrator for the HealthSharesTM Indexes, a series of 20 underlying indexes for the HealthSharesTM Exchange Traded Funds, today announced the quarterly rebalancing of the Indexes. The following securities will be added and deleted in the Indexes effective before...

  Articles 2008-06-17

• Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration

  First Presentation of Full Data Set from the TRIUMPH-1 Trial of Inhaled Treprostinil SILVER SPRING, Md., May 21 /PRNewswire-FirstCall/ -- United Therapeutics Corporation and its wholly-owned subsidiary Lung Rx, Inc. today announced that data from seven presentations concerning the treatment of pulmonary arterial hypertension PAH with...

  Articles 2008-05-21

• Treprostinil Data to be Presented at Annual Meeting of the American Thoracic Society

  United Therapeutics to Hold Investor Q&A Session Following Conclusion of ATS Conference SILVER SPRING, Md., May 6 /PRNewswire-FirstCall/ -- United Therapeutics Corporation and its wholly-owned subsidiary Lung Rx, Inc. today announced that data related to the four different routes of administration of the drug, treprostinil, for...

  Articles 2008-05-06

• United Therapeutics Corp. announces an increase in its first quarter

  United Therapeutics Corp., of Silver Spring, a biopharmaceutical company that is developing drugs to treat cardiovascular, infectious and oncological diseases, reported first-quarter net income increased 55 percent to $11.4 million, or 47 cents per diluted share, compared to a net loss of $2.8 million, or 13 cents per diluted share,...

  Articles 2008-05-02

• Silver Spring-based United Therapeutics Corp. exec's profitable deal

  The president and chief operating officer of Silver Spring-based biotechnology company United Therapeutics Corp. exercised options for and then sold 3,500 shares of common stock, according to a Securities and Exchange Commission filing Friday. In a Form 4 filed with the SEC, Roger Jeffs reported exercising the options Thursday for...

  Articles 2008-04-23

• Aradigm Initiates Trial of Lung Rx's Inhaled Treprostinil

  Bridging Study Compares AERx Essence([R]) System to Nebulizer Used in Phase 3 TRIUMPH trial HAYWARD, Calif. -- Aradigm Corporation (OTCBB: ARDM) (the "Company") today announced it initiated a bridging clinical trial of inhaled treprostinil utilizing its AERx Essence([R]) pulmonary delivery system. The trial in healthy volunteers is being...

  Articles 2008-04-08

• UTHR, UTSI, UVSP, VLCCF, VRML, ZUMZ Have Also Been Added To Naked Short List Today.

  M2 PRESSWIRE-2 April 2008-BUYINS.NET: UTHR, UTSI, UVSP, VLCCF, VRML, ZUMZ Have Also Been Added To Naked Short List TodayC1994-2008 M2 COMMUNICATIONS LTD RDATE:02042008 BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and...

  Articles 2008-04-02

• Silver Spring-based United Therapeutics earns less

  United Therapeutics Corp., of Silver Spring, which develops pharmaceuticals to treat cardiovascular, infectious and oncological diseases, said fourth-quarter profit fell 96 percent as expenses rose sharply and the year-earlier quarter benefited from a hefty tax gain. For the quarter ended Dec. 31, the company earned $2 million, or 8 cents...

  Articles 2008-02-20

• United Therapeutics earns less [Derived headline]

  Art Dept.: Please let Paul know if this is too long or if there's overrun or not enough room to run logos Logos available for United Therapeutics, Novavax, Martek, MedImmune, Mercy Medical Center, Capital Source United Therapeutics earns less United...

  Articles 2008-02-20

• Has added United Therapeutics Corp. to their watch list.

  M2 PRESSWIRE-13 February 2008-investorIM: Has added United Therapeutics Corp. to their watch listC1994-2008 M2 COMMUNICATIONS LTD RDATE:13022008 InvestorIM has been created as a tool for the average investor. The idea is simple, a website where the world can communicate. Do...

  Articles 2008-02-13

• United Therapeutics to Announce Fourth Quarter and Annual 2007 Financial Results Before Market Open on Tuesday, February 19, 2008.

  M2 PRESSWIRE-12 February 2008-The Maybach Review: United Therapeutics to Announce Fourth Quarter and Annual 2007 Financial Results Before Market Open on Tuesday, February 19, 2008C1994-2008 M2 COMMUNICATIONS LTD RDATE:12022008 Maybach Financial is a syndicate of financial informants representing...

  Articles 2008-02-12

• Global Review on United Therapeutics Corporation.

  M2 PRESSWIRE-12 February 2008-The SI Report: Global Review on United Therapeutics CorporationC1994-2008 M2 COMMUNICATIONS LTD RDATE:12022008 Streetinvesting.com has now resumed our progressive review of United Therapeutics Corporation (Nasdaq: UTHR) after it traded up 1% Tuesday, late in the morning...

  Articles 2008-02-12